Matthew Meriggioli MD

Neuromuscular Medicine

Executive Director, Neuroscience Translational Medicine Head, Neuromuscular Disease

1740 W Taylor StChicago, IL 60612
Phone+1 866-600-2273
Fax+1 312-563-4155

Dr. Meriggioli is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Meriggioli's full profile Already have an account?

Education & Training

Loyola University Medical CenterResidency, Neurology, 1991 - 1994
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1990 - 1991
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 1993 - 2023

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017

Clinical Trials

A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
UNKNOWN
EARLY_PHASE1

Publications & Presentations

PubMed

21 citations
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
Baltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, Ronenn Roubenoff, Pascal Espié
Journal of Clinical Neuroscience. 2024-01-01
220 citations
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
Jerry R. Mendell, Samiah Al-Zaidy, Kelly J. Lehman, Markus McColly, Linda Lowes
JAMA Neurology. 2021-07-01
87 citations
Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy.
Payam Mohassel, Océane Landon-Cardinal, A. Reghan Foley, Sandra Donkervoort, Katherine Pak
Neurology(R) Neuroimmunology & Neuroinflammation. 2019-01-01

Grant Support

12th International Conference On Myasthenia Gravis And Related DisordersNational Institute Of Neurological Disorders And Stroke2011–2012
Immunoregulation Of Experimental Autoimmune Myasthenia GravisNational Institute Of Neurological Disorders And Stroke2007–2011